Most Popular

Most Popular News

February 18, 2017

Circulating tumor DNA illuminates the genomic landscape of mRCC and highlights potential resistance mechanisms.

Read more

February 18, 2017

Computer-assisted response evaluation could reduce errors and time spent in assessing tumor response in mRCC.

Read more

February 18, 2017

Active surveillance is a safe option for selected patients with small renal masses, according to DISSRM registry study.

Read more

February 17, 2017

Novel phase III trial finds single cycle of BEP can reduce exposure, prevent most recurrences in testicular cancer.

Read more

February 17, 2017

After a median 10 years of follow-up, the BC2001 trial confirmed that adding chemotherapy to RT improves salvage cystectomy rate, locoregional control, and bladder cancer–specific survival over RT alone in muscle-invasive bladder cancer.

Read more

February 17, 2017

Although BCG remains the primary therapy for patients with NMIBC, many patients have disease that is resistant to this treatment or relapses. Optimal treatment for patients with what is now considered BCG-unresponsive NMIBC remains to be established.

Read more

February 17, 2017

ASCO and NCCN announce a joint collaboration to publish practical clinical guidance on the management of side effects caused by immunotherapy.

Read more

February 16, 2017

Prostate cancer can be subtyped based on cell of origin, into luminal A, luminal B, and basal cell subtypes, according to a new study (Abstract 3). Luminal B prostate cancer has the poorest prognosis, but also derives the most benefit from ADT.

Read more

February 16, 2017

Adding mitoxantrone/prednisone to ADT in patients with high-risk prostate cancer who underwent prostatectomy increased the risk of leukemia and did not improve overall or prostate cancer–specific survival in a randomized phase III trial.

Read more

February 16, 2017

Experts discussed differences in active surveillance guidelines in Canada, the United Kingdom, and the United States and how genomic tests and imaging play a role in this disease management strategy.

Read more
February 13, 2017

Experts review the current research and questions regarding the optimal perioperative strategy for the treatment of renal cell carcinoma.

Read more
February 9, 2017

At the present time, genetic evaluation guidelines for prostate cancer primarily focus on BRCA1 and BRCA2 testing. The overall risk of prostate cancer has been reported up to 3.8-fold for men who carry BRCA1 mutations and up to 8.6-fold for men who carry BRCA2 mutations.

Read more
February 9, 2017

Active surveillance has emerged as a therapeutic strategy for small renal masses in patients for whom the risks of surgical treatment may outweigh the oncologic benefits of resection.

Read more
February 9, 2017

Dr. Jeanny B. Aragon-Ching discusses the pros and cons of new treatments for patients with oligometastatic prostate cancer.

Read more
February 9, 2017

Experts discuss the current imaging techniques for staging and managing muscle-invasive and metastatic bladder cancer, as well as other promising imaging options currently being studied. 

Read more

February 9, 2017

Dr. Neha Vapiwala highlights the findings from the ProtecT trial, which compared surgery, radiation, and active surveillance for the treatment of localized prostate cancer.

Read more

February 9, 2017

The United States and United Kingdom treat prostate cancer differently when it comes to active surveillance. Read why.

Read more

February 9, 2017

Dr. David J. McConkey will discuss immunology in bladder cancer during the urothelial carcinoma keynote lecture.

Read more

February 9, 2017

During his keynote lecture, Dr. Lawrence H. Einhorn will talk about risk stratification, clinical management, and late complications of chemotherapy for testicular cancer.

Read more

February 9, 2017

Dr. Matthew Milowsky will give the urothelial carcinoma year in review lecture at the 2017 GU Symposium. He will focus on developments in immuno-oncology in metastatic urothelial cancer.

Read more